The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

Penmenvy is a combination of GSK's already-approved vaccines Bexsero and Menveo, which together brought in more than £1.4 billion (around $1.8 billion) in sales last year with double-digit growth ...

Mar. 5, 2025 — A live-attenuated tuberculosis (TB) vaccine candidate in development elicits a much more balanced and effective immune response compared to the existing vaccine used across much ...